

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this supplemental announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this supplemental announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

SUPPLEMENTAL ANNOUNCEMENT
CONNECTED TRANSACTION
PARTICIPATION IN THE
ESTABLISHMENT OF THE GP VENTURE CAPITAL FUND

Reference is made to the announcement of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) dated 19 December 2023 (the “**Announcement**”) in relation to the connected transaction of participating in the establishment of GP Venture Capital Fund. Capitalized terms used herein have the same meanings as those defined in the Announcement unless the context otherwise specified.

Based on the information currently available and having made all reasonable enquiries, the Company confirms that Industrial Investment Special Master Fund is owned as to 99.98% by Guangzhou Industrial Investment Holding Group Co., Ltd., which in turn is ultimately owned by the Guangzhou Municipal People’s Government, holding 91.55% of its equity interests and the Department of Finance of Guangdong Province, holding 8.45% of its equity interests.

Guangzhou Industrial Investment Holding Group Co., Ltd. is a company established in the PRC with limited liability and is principally engaged in financial consulting, corporate management, investment activities with own funds, venture capital (limited to investment in unlisted enterprises).

Save as disclosed above, all other information in the Announcement shall remain unchanged.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 5 January 2024

As at the date of this supplemental announcement, the Board comprises Mr. Li Chuyuan, Mr. Yang Jun, Ms. Cheng Ning, Ms. Liu Juyan, Mr. Zhang Chunbo, Mr. Wu Changhai and Mr. Li Hong as executive directors, and Mr. Chen Yajin, Mr. Huang Min, Mr. Wong Lung Tak Patrick and Ms. Sun Baoqing as independent non-executive directors.